MedTrace Logo

Z-Drugs for Sleep Disorders in Alzheimer's Disease

NCT03075241 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2020-11-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether Zolpidem and Zoplicone are efective in the treatment of sleep disorders in Alzheimer's disease (AD)

Conditions

Interventions

DRUG

Zolpidem

Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights

DRUG

Zoplicone

Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights

DRUG

Placebo

Inactive or inert pill which will be used as a comparator

Sponsors & Collaborators

  • Brasilia University Hospital

    lead OTHER

Principal Investigators

  • Luciana L. Louzada, MD, MsC · Brasilia University - Brasilia's University Hospital - Geriatric Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03075241 on ClinicalTrials.gov